Geoffrey Ku, MD
Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
Geoffrey Ku, MD is a medical oncologist, who specializes in the treatment of gastrointestinal cancers, including esophagogastric, pancreaticobiliary and colorectal cancer. He was born in Singapore and came to the U.S. for college, where he attended Stanford University in Stanford, California. He then graduated from the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania, where he was elected to the Alpha Omega Alpha Honors Society. He completed his internship and residency in Internal Medicine at the New York-Presbyterian Hospital, Weill Cornell Campus in New York, New York, where he was selected to be an Assistant Chief Resident. He then moved across First Avenue for his Medical Oncology fellowship at Memorial Sloan Kettering Cancer Center, where he performed mentored research with Dr. David Ilson during the second and third year of his fellowship. At the completion of his fellowship, he also spent a year as a Research Fellow at the Ludwig Institute of Cancer Research, MSKCC, where he worked with Drs. Lloyd Old, James Allison and Jedd Wolchok on immune correlative assays for the then incipient field of immune checkpoint inhibition. After spending two years in Singapore as a consultant at Johns Hopkins International Medical Center, he returned to MSKCC, where he has attended on the Gastrointestinal Oncology Service since 2012. He is currently the Head of the Esophagogastric section.
Dr. Ku’s research interest involve the evaluation of novel therapies, including immunotherapy, in advanced esophagogastric cancer and the incorporation of these agents into combined modality therapy for locally advanced disease. Recent first-author publications have been in the Journal of Clinical Oncology and Cancer. He previously served on the American Society of Clinical Oncology Scientific Program Committee, where he was the track leader for the GI (non-colorectal) cancer group. He is currently a member of the NRG Oncology Gastrointestinal committee and was recently appointed to be an NRG representative on the Esophagogastric Task Force of the National Cancer Institute.